Dong-A’s Biological Products to Enter Eastern Europe Markets
According to Korean online trade publication, Daily Pharm, Korean drugmaker Dong-A Pharmaceutical said that it has entered into an agreement with Ukrainian companies to export its products over five years.
According to Daily Pharm, the company will export growth hormone Growtropin, cancer drug Gemcit and tuberculosis drug Closerin.
The publication added that the company made contracts with Turkish companies Dr. Frik and DELilac and Russian company Mir Pharm last June and July to export its biological products.
The company said it is in talks with Commonwealth of Independent States to export its biological products and plans to enter the European biological product market and is considering a free trade agreement with Europe Union in the near future, according to the publication.